PRF Technologies Ltd. income statement
In fiscal 2025, PRF Technologies Ltd. reported revenue of $17,000, operating income of −$5.1m (a -30129.4% margin) and net income of −$5.0m, or −$7.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 |
| Gross profit | 0 | 0 | −0 |
| Research and development | 6 | 12 | 1 |
| Selling, general and administrative | 2 | 1 | 1 |
| Operating income | −10 | −15 | −5 |
| Income before tax | −9 | −15 | −5 |
| Income tax | 0 | 0 | 0 |
| Net income | −9 | −15 | −5 |
| Diluted EPS | −$122.94 | −$105.52 | −$7.47 |
| Diluted shares (average) | — | — | — |
| EBITDA | −10 | −15 | −5 |
Compare with peers
- Akanda Corp. income statement
- Talphera, Inc. income statement
- Scienture Holdings, Inc. income statement
- 60 Degrees Pharmaceuticals, Inc. income statement
- China SXT Pharmaceuticals, Inc. income statement
Head to head: AKAN vs PRFXPRFX vs TLPHPRFX vs SCNX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies